Cystic Fibrosis Foundation Therapeutics, Inc. And Predix Pharmaceuticals Announce Drug Discovery Collaboration To Treat Cystic Fibrosis
10/19/2005 5:13:01 PM
WOBURN, Mass. & BETHESDA, Md.--(BUSINESS WIRE)--March 16, 2005--Predix Pharmaceuticals Holdings Inc., a drug discovery and development company, and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced today that they have signed a research, development and commercialization agreement. The company will receive up to $12.5 million in milestone-driven funds over the next three years through a therapeutics development award from CFFT for two programs.
Cystic fibrosis (CF) is a genetic disease affecting approximately 30,000 children and adults in the United States. A defective gene causes the body to produce an abnormally thick, sticky mucus that clogs the lungs, leading to life-threatening lung infections, and obstructs the pancreas, causing difficulty absorbing food. The median life expectancy has improved from early childhood to the mid-30s today, but many individuals battle lung disease for years.